Sheridan K. Snedden
61 IP cases indexed. Covers patent matters.
Cases Presided Over
61 cases indexed | Page 1 of 3
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
The PTAB found all 28 challenged claims unpatentable in this IPR proceeding concerning oncology/immunotherapy. The Petitioner successfully demonstrated that the MSI-H Study Record inherently anticipated or rendered obvious the claimed methods under both § 102 and § 103.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
The PTAB issued a Final Written Decision finding multiple claims of the '975 patent unpatentable. The petitioner successfully demonstrated that the claimed methods and drug characteristics were anticipated (102) or rendered obvious (103) by prior art, primarily the MSI-H Study Record (MSR).
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
The PTAB issued a Final Written Decision finding that all seven claims of the patent were unpatentable. The petitioner successfully demonstrated anticipation (102) and obviousness (103) based on the MSI-H Study Record, which was deemed prior art despite arguments regarding experimental use exceptions.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
The PTAB found all 36 challenged claims unpatentable by both anticipation (35 U.S.C. § 102) and obviousness (35 U.S.C. § 103). The Board concluded that the MSI-H Study Record inherently anticipates the claimed methods, including those requiring pre-treatment testing for microsatellite instability high or DNA mismatch repair deficient status. This decision significantly weakens the patent's validity in the context of oncology and immunotherapy.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
The PTAB found all 30 challenged claims unpatentable by anticipation (102) and obviousness (103). The Petitioner successfully argued that the MSI-H Study Record anticipates the claimed methods for treating non-colorectal MSI-H cancers.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
The PTAB found that the patent claims were unpatentable under both anticipation (35 U.S.C. § 102) and obviousness (35 U.S.C. § 103). The Board concluded that the MSI-H Study Record anticipates the claimed invention by teaching all elements, leading to a final decision against the patent owner.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
The PTAB issued a Final Written Decision finding all 38 claims of the '491 patent unpatentable. The Board construed "in response to" as requiring a causal link between MSI-H/dMMR determination and treatment, which led to a finding that the MSR anticipated and rendered obvious the challenged claims.
NEURENT MEDICAL INC. et al. v.The Foundry, LLC et al.
The Petitioner successfully demonstrated that multiple claims of the '077 patent were unpatentable over various combinations of prior art references. The Board found that a Person Having Ordinary Skill in the Art (POSA) would have been motivated to combine existing RF ablation and nasal treatment technologies.
Salvacion USA, Inc. et al. v.Trutek Corp.
The Petitioner successfully demonstrated that the challenged claims (1-3 and 8) were anticipated by multiple prior art references, including Chen. The Board found that the prior art disclosed all claim elements, leading to a final decision of unpatentability.
Dr. Squatch, LLC v.The Procter & Gamble Company
The PTAB issued a Final Written Decision finding all 15 challenged claims unpatentable. The Board found that the claimed deodorant stick compositions were anticipated or obvious over various combinations of prior art references. This decision heavily favors the Petitioner, Dr. Squatch, LLC, by invalidating the patent's scope.
Dr. Squatch, LLC v.The Procter & Gamble Company
The PTAB issued a Final Written Decision finding all 18 challenged claims of U.S. Patent No. 11,540,999 B2 unpatentable based on obviousness (35 U.S.C. § 103). The Board found that various combinations of prior art references taught or suggested the claimed aluminum-free deodorant compositions and structures.
Dr. Squatch, LLC v.The Procter & Gamble Company
The PTAB found that the petitioner's challenges against claims 1-7, 9-13, and 16-19 were successful. The Board determined that the challenged deodorant formulations were unpatentable under both 35 U.S.C. § 102 (anticipation) and § 103 (obviousness).
Dr. Squatch, LLC v.The Procter & Gamble Company
The PTAB issued a final written decision finding all 23 challenged claims of U.S. Patent No. 11,497,706 unpatentable. The petitioner successfully demonstrated that the claimed aluminum-free deodorant compositions were anticipated or rendered obvious by various combinations of prior art references.
Dr. Squatch, LLC v.The Procter & Gamble Company
The PTAB found all 19 challenged claims unpatentable based on obviousness (35 U.S.C. § 103). The Petitioner successfully demonstrated that a Person Having Ordinary Skill in the Art would have been motivated to combine various prior art references for predictable results. This decision confirms the validity of the combination approach under POSA principles in deodorant formulation technology.
Front Line Medical Technologies Inc. v.Prytime Medical Devices, Inc.
Petitioner successfully demonstrated that all ten challenged claims related to vascular occlusion catheters are unpatentable by a preponderance of the evidence. The Board relied heavily on various combinations of prior art references, primarily under 35 U.S.C. § 103 (obviousness).
3D Diagnostix, Inc. v.Watson Guide IP, LLC
The PTAB found that all challenged claims were obvious over various combinations of prior art references, including Llop '126 and Sichuan. The Board determined there was a clear motivation for a person skilled in the art to combine these references to achieve the claimed invention.
Jeisys Medical Inc. et al. v.Serendia, LLC
The PTAB instituted an IPR challenging claims 13 and 14 of Serendia's patent, finding a reasonable likelihood of anticipation by the prior art reference Mehta. The case moves to trial phase after rejecting arguments for discretionary denial based on competitor relationships.
Jeisys Medical Inc. et al. v.Serendia, LLC
The PTAB instituted the IPR challenge against Serendia's '536 patent, finding a reasonable likelihood of unpatentability. The Board determined that prior art (Mehta) discloses the claimed depth control feature despite arguments for fixed-length needles.
Ilooda Co., Ltd. et al. v.Serendia, LLC
The PTAB institution decision found a reasonable likelihood of unpatentability for several claims in the dermatological treatment patent, primarily based on anticipation by reference Mehta. The Board rejected arguments for discretionary denial and proceeded with the IPR.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
Merck Sharp & Dohme LLC successfully convinced the PTAB to institute IPR proceedings against The Johns Hopkins University regarding anti-cancer therapies using PD-1 blockade. The Board found sufficient evidence that prior art, including the MSI-H Study Record, renders several claims unpatentable.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
Merck Sharp & Dohme LLC successfully secured institution for its IPR challenge against The Johns Hopkins University regarding oncology/immunotherapy claims. The Board found sufficient evidence to proceed under 35 U.S.C. § 102 and § 103, despite procedural challenges from the Patent Owner.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
Merck Sharp & Dohme LLC successfully instituted an IPR against The Johns Hopkins University's patent, challenging claims related to anti-PD-1 antibodies for MSI-high cancer. The Board found sufficient evidence that prior art anticipated and rendered the claims obvious, leading to a trial institution decision.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
Merck Sharp & Dohme LLC successfully petitioned to institute IPR against The Johns Hopkins University regarding claims related to anti-PD-1 antibody treatment for MSI colorectal cancer. The Board found a reasonable likelihood of success under both 102 and 103 grounds across all 36 claims at issue.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
Merck Sharp & Dohme LLC successfully petitioned to institute IPR proceedings against The Johns Hopkins University regarding a patent on immunotherapy methods. The Board found reasonable likelihood of unpatentability under both 102 and 103, primarily based on the MSI-H Study Record.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
Merck Sharp & Dohme LLC successfully challenged The Johns Hopkins University's patent claims regarding MSI-H cancer treatment, leading the PTAB to institute proceedings. The petitioner argued that the claimed methods were anticipated by or obvious over existing prior art, including the MSI-H Study Record and various medical literature.
NEURENT MEDICAL INC. et al. v.The Foundry, LLC et al.
NEURENT MEDICAL INC. successfully petitioned PTAB for institution of IPR against THE FOUNDRY, LLC's nasal cavity treatment patent (11679077). The Board found sufficient evidence across multiple grounds of anticipation and obviousness to proceed to trial.
Salvacion USA, Inc. et al. v.Trutek Corp.
Salvacion USA successfully achieved institution in the IPR against Trutek Corp.'s nasal application formulations, facing challenges of anticipation and obviousness over prior art including Chen. The Board found Petitioner's arguments persuasive on the record after detailed claim construction, setting the stage for a full trial.
Ovid Therapeutics Inc. v.Marinus Pharmaceuticals, Inc.
Ovid Therapeutics Inc.'s IPR challenge against Marinus Pharmaceuticals, Inc. was denied by the PTAB on grounds of obviousness (103). The Board found that Petitioner failed to demonstrate a reasonable likelihood of prevailing in its challenges regarding plasma concentration limitations and priority.
Vectair Systems Inc. v.Fresh Products, Inc.
Vectair Systems Inc.'s IPR challenge against Fresh Products, Inc.'s patent was denied by the PTAB. The Board found that the Petitioner failed to establish a reasonable likelihood of prevailing on grounds of anticipation (102) or obviousness (103).
Dr. Squatch, LLC v.The Procter & Gamble Company
Dr. Squatch successfully petitioned against Procter & Gamble's deodorant patent, leading the PTAB to institute the case after finding a reasonable likelihood of unpatentability. The Board found multiple grounds of obviousness (35 U.S.C. § 103) across various claims using combinations of prior art references.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.